INCI
INCI NAMEv2.0
enkozhja
原料辞典検索/hydrolyzed-hyaluronic-acid/HYDROLYZED HYALURONIC ACID
Tier 1 Monograph · SSOT 15 FieldsRaw .md (GEO) ↗
合成 (Synthetic)

HYDROLYZED HYALURONIC ACID

日本化粧品工業連合会 (JCIA) 表示名称: 加水分解ヒアルロン酸
ヘアコンディショニング剤保湿剤（ヒューメクタント）皮膚コンディショニング剤
[EU CosIng Official Definition] Hydrolyzed Hyaluronic Acid is the hydrolysate of Hyaluronic Acid derived by acid, enzyme or other method of hydrolysis
結論先行 エグゼクティブ規制・安全性ファクトボックスAEO / GEO CITATION ANCHOR

化粧品における 加水分解ヒアルロン酸 (HYDROLYZED HYALURONIC ACID) のグローバル配合基準と処方特性とは？

加水分解ヒアルロン酸（標準 INCI: HYDROLYZED HYALURONIC ACID、CAS番号: N/A）は、化粧品処方において主にヘアコンディショニング剤, 保湿剤（ヒューメクタント）, 皮膚コンディショニング剤として配合される原料です。日本厚労省/JCIA（規制なし）、韓国MFDS（規制なし）、欧州CosIng（規制なし）など6大法域の法定基準下で管理され、通常 0.05–0.1%（適正安定域 pH 4–8）で処方されます。

7大トラック 国別・用途別 公式全成分表示名称マトリクス

各国公的告示原典のみ収録 · 機械翻訳・任意音訳ゼロ
7-Track Official Statutory Label Names for HYDROLYZED HYALURONIC ACID
法域・規制トラック公式全成分表示名称ワンクリックコピー
① 韓国 (MFDS 化粧品標準名称)HYDROLYZED HYALURONIC ACID (KR MFDS Registered)
② 韓国旧名称履歴 (301 リダイレクト)——
③ 欧州連合 (EU CosIng EC 1223/2009)HYDROLYZED HYALURONIC ACID
④ 米国一般化粧品 (US PCPC / MoCRA INCI)HYDROLYZED HYALURONIC ACID
⑤ 米国 FDA OTC モノグラフ有効成分名— (米国 OTC 対象外 / 一般化粧品原料)—
⑥ 中国 (NMPA IECIC 標準中国語名称)水解透明质酸
⑦ 日本化粧品表示名称 / 医薬部外品外原規名称 (JCIA / MHLW)加水分解ヒアルロン酸 · [QD: 加水分解ヒアルロン酸]

Layer 1 — 6大法域 法定配合上限および規制ステータス

Layer 1 Statutory Regulatory Limits Across 6 Regions for HYDROLYZED HYALURONIC ACID
法域規制ステータス配合上限制限条件および一次法源出典
韓国 (MFDS)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)
欧州 (EU)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)
米国 (FDA)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)
中国 (NMPA)配合可能GMPIECIC Entry #6353
日本 (MHLW)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)
ASEAN (ACD)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)

Layer 2 — 毒性・安全性評価上限 (US CIR / EU SCCS / CN IECIC)

「欧州 SCCS 安全性評価上限」は消費者安全科学委員会が安全域 (MoS≥100) と判定した毒性学的上限であり、「米国 CIR 市販製品最大報告濃度」および「中国 IECIC 最高歴史使用量」は市販製品における最大実績濃度です。

Layer 2 Toxicological & Historical Safe Use Concentrations for HYDROLYZED HYALURONIC ACID
安全性評価基準適用範囲・用途安全濃度範囲判定結果および文献参照
中国 IECIC 最高歴史使用量leave_on≤ 2%安全判定 (MoS≥100)NMPA IECIC (2025) Entry 06154 (2025)
中国 IECIC 最高歴史使用量rinse_off≤ 1.5%安全判定 (MoS≥100)NMPA IECIC (2025) Entry 06154 (2025)
⚠️ 参考用案内 (免責事項): 本辞典の成分名・規制上限・処方ガイドは研究開発の参考用です。法改正の時差やデータの誤記・漏れがあり得るため、実際の処方・ラベル表示・届出前には必ず管轄当局の最新告示原文をご確認ください。本情報の利用により生じた問題について運営主体は法的責任を負いません。
Interactive Quartile Box-Plot (Min–Q1–Median–Q3–Max)

Layer 3 Formulation Concentration Box-Plot vs. Statutory Limit

Aqueous Serum / Ampoulen=6
Min 0.05% · Q1 0.0625% · Median 0.1% · Q3 0.1% · Max 0.1%
Emulsion / Creamn=17
Min 0.03% · Q1 0.1% · Median 0.1% · Q3 0.1% · Max 0.5%
Aqueous Serum / Ampoule — Aqueous serum, toner & hydrogel matrix formulation component
Verified Source: Global Starter Formulation Library Statistical Distribution (n=6, EVONIK 6) (cir_safety) · EVONIK 6
Typical Median: 0.1%

Layer 3 — 剤形別通常配合濃度 (四分位数 n≥5) & 物理化学・相溶性ガイド

Layer 3 Formulation Concentration Quartiles by Product Category for HYDROLYZED HYALURONIC ACID
剤形グループMin – Q1 – Median – Q3 – Max (%)処方役割・作用機序Source ID
剤形群 A — 水성化粧水・美容液・アンプル0.05% · 0.0625% · 0.1% · 0.1% · 0.1%Aqueous serum, toner & hydrogel matrix formulation componentGlobal Starter Formulation Library Statistical Distribution (n=6, EVONIK 6)
剤形群 B — 乳液・エマルジョン・クリーム0.03% · 0.1% · 0.1% · 0.1% · 0.5%Emulsion cream & lotion structural / conditioning agentGlobal Starter Formulation Library Statistical Distribution (n=17, EVONIK 17)
Cutaneous Permeation Science (500 Dalton Rule)MW: Macro/Complex · LogP: N/A

Stratum Corneum Penetration Depth & Bio-Spicule Transdermal Delivery

Stratum Corneum (Brick & Mortar Barrier · 10–20 µm)500 Da Molecular Weight Cutoff BarrierViable Epidermis (Keratinocytes & Melanocytes · 50–100 µm)Target for Brightening (Tyrosinase/Melanosome) & Barrier LipidsPapillary Dermis (Fibroblasts & ECM Collagen · 150–300 µm)Target for Collagen I/III Synthesis, Peptides, PDRN & ExosomesEpidermal Passive Permeation (<500 Da)
Molecular Weight & LogP Permeation Diagnosis
Low Molecular Weight (320 Da ≤ 500 Da) — Passive Permeation Feasible

Under passive topical application, molecules diffuse tortuously through intercellular lipids. Hydrophilic compounds >500 Da remain primarily on the outer stratum corneum.

Estimated Target Depth
40–90 µm
Optimal Delivery System
Polyol Enhancer / Serum
Colloid Interface, pH Spectrum & Thermal Stability

pH Stability Window (0–14), Thermal Limit & HLB Colloidal Phase Behavior

Water or glycol phase soluble/dispersible
Optimal Formulation pH Stability Window (0–14)pH 4.0 – 8.0
0245.5791114

Outside pH 4–8, risk of hydrolysis, viscosity loss, or ionic dissociation increases.

Maximum Thermal Processing Limit (°C)≤ 50°C
25°C45°C60°C75°C85°C100°C

Thermally stable up to 50°C during standard emulsification.

HLB Scale (0–20) & Colloidal Micelle / Lamellar Phase Simulator
O/W Oil-in-Water Micelle Emulsion (Lotion / Cream)
HLB 11.5
W/O (3–6)Lamellar (8–10.5)O/W Emulsion (11–15)Solubilizer (15–19)O/W Droplet
Biochemical Signaling & Mechanism Pathway

Cellular & Molecular Target Mechanism Flow

1. Epidermal Interaction→ Upregulation / Activation
Intercellular Lipid & Hydration Matrix
→
TEWL Reduction & Barrier Conditioning
2. Homeostasis Modulation⊣ Inhibition / Blockade
Oxidative Stress (ROS) & Irritant Cascade
⊣
Cutaneous Soothing & Homeostasis
Formulation Ontology Radial Graph

Interactive Synergy Pairings (Solid) & Incompatibility Warnings (Dashed)

+ GLYCERIN+ CAPRYLIC/CAPRIC TR…+ TOCOPHEROL✕ Verify phase compati…HYDROLYZED HYALURO…
Interactive Node Guide

Click any green synergy node to jump directly to its monograph, or click a red dashed node to inspect the chemical incompatibility mechanism.

+ GLYCERIN+ CAPRYLIC/CAPRIC TRIGLYCERIDE+ TOCOPHEROL
代表商品名参考 (商標法第90条第1項第2号 記述的表示)
HYDROLYZED HYALURONIC ACID

商品名は研究者がグレードを識別するための参考表記であり、各商標権は原メーカーに帰属します。

学術・毒性・処方統合モノグラフ

Tier 1 Synthesis

本原料に紐づく NIH PubMed 査読付き論文アブストラクトおよび公的毒性評価報告書のみに基づいて作成された学術要約です。

■ [1. Chemical Identity & International Labeling Nomenclature] - INCI Name: HYDROLYZED HYALURONIC ACID | CAS No.: N/A | EC No.: N/A - Origin: SYNTHETIC | Functions: , , - Physicochemical Profile: Formula | MW /(Polymer/Complex) | / | Ionic Nature: non-ionic | CosIng/MFDS - Official Regional Label Names: US [HYDROLYZED HYALURONIC ACID] · EU [HYDROLYZED HYALURONIC ACID] · CN [水解透明质酸] · JP [加水分解ヒアルロン酸] · JP Quasi-Drug [加水分解ヒアルロン酸] ■ [2. Dermatological Mechanism of Action & Functional Role] - Hydrolyzed Hyaluronic Acid is the hydrolysate of Hyaluronic Acid derived by acid, enzyme or other method of hydrolysis Classified under origin 'synthetic', it acts within the cosmetic vehicle or stratum corneum to deliver , , performance and structural formulation stability. ■ [3. Global 6-Jurisdiction Regulatory Status & Safety Limits (Layer 1 & Layer 2)] - Regional Summary: KR: NONE | EU: NONE | US: NONE | CN: ALLOWED | JP: NONE | ASEAN: NONE (CN IECIC (2025) Entry No. 6353 (水解透明质酸)) - No specific Annex prohibition or numeric restriction across the 6 major jurisdictions (Permitted under general GMP safety assessment). - Official Safety & Historical Use Concentration (Layer 2): CN_IECIC_2025 (cn_iecic_max, leave_on): Max 2.0% / CN_IECIC_2025 (cn_iecic_max, rinse_off): Max 1.5% ■ [4. Formulation Dosage Guide by Product Category (Layer 3-A)] - [aqueous_serum] Typical range: 0.05 ~ 0.1% (Median 0.1%, Ref: Global Starter Formulation Library Statistical Distribution (n=6, EVONIK 6)) — Aqueous serum, toner & hydrogel matrix formulation component - [emulsion_cream] Typical range: 0.03 ~ 0.5% (Median 0.1%, Ref: Global Starter Formulation Library Statistical Distribution (n=17, EVONIK 17)) — Emulsion cream & lotion structural / conditioning agent ■ [5. Formulation Engineering, Stability & Incompatibility Matrix (Layer 3-B)] - Addition Phase: Water Phase or Cool-down Phase (< 45°C) - Optimal pH Range: pH 4.0 ~ 8.0 | Max Process Temp: Max 50°C | Electrolyte Tolerance: MEDIUM - Incompatibility / Caution: Verify phase compatibility under extreme pH or high electrolyte loads - Synergy Pairings: GLYCERIN, CAPRYLIC/CAPRIC TRIGLYCERIDE, TOCOPHEROL | Reference Trade Names: HYDROLYZED HYALURONIC ACID ■ [6. Peer-Reviewed Literature & Official Compendia Evidence] - PMID 36547309 (2022, Gels): Fabrication of High-Resolution Fine Microneedles Derived from Hydrolyzed Hyaluronic Acid Gels in Vacuum Environment Impr - PMID 31376454 (2019, Int J Biol Macromol): Various methods to combine hyaluronic acid and antimicrobial peptides coatings and evaluation of their antibacterial beh - PMID 13076197 (1953, Science): Inactivation of vaccinia virus by a diffusible component from hydrolyzed hyaluronic acid

関連査読付き学術論文 (NIH PubMed) (3)

Fabrication of High-Resolution Fine Microneedles Derived from Hydrolyzed Hyaluronic Acid Gels in Vacuum Environment Imprinting Using Water Permeable Mold [PMID: 36547309 · 2022]
Miura S, Yamagishi R, Miyazaki R, Yasuda K, Kawano Y, Yokoyama Y, Sugino N, Kameda T, Takei S · Gels (2022)

Hydrolyzed hyaluronic acid high-resolution fine microneedles of 13 &#xb5;m in diameter and 24 &#xb5;m in height were fabricated from hydrolyzed hyaluronic acid gels made in mixtures of water using vacuum environment imprint lithography processes with a water permeable mold. The gas traps of water and volatile solvents in the imprint materials cause transfer failure in the conventional water impermeable molds of quartz and metal. However, the water permeable mold allows the use of 67 wt% dilution water with high solubility to increase the fluidity of the hydrolyzed hyaluronic acid during the patterning of high-resolution fine microneedles for cosmetics and pharmaceuticals. This demonstration sets a new paradigm of functional pure gels for high-resolution nano-patterning applications with various cosmetic and pharmaceutical materials containing dilution water using a water permeable mold.

Various methods to combine hyaluronic acid and antimicrobial peptides coatings and evaluation of their antibacterial behaviour [PMID: 31376454 · 2019]
Paris JB, Seyer D, Jouenne T, Th&#xe9;bault P · Int J Biol Macromol (2019)

To prevent bacterial adhesion and contamination, biomaterials exhibiting both antiadhesive and biocidal properties are the most promising way. However, control of the properties combination is not so easy due, in particular, to antagonist mechanisms. Antibacterial surfaces against Staphylococcus epidermidis adhesion were here elaborated by using both nisin grafting and repelling polysaccharide coating. We evaluated two strategies aiming to improve the antimicrobial peptide (AMP) immobilization parameters (i.e., the accessibility and/or local density) in order to obtain the best antimicrobial activity on surfaces. We thus (i) grafted the nisin on a surface previously coated with hydrolyzed hyaluronic acid (HA) (to decrease the length of the polysaccharide chains) or (ii) coupled nisin and HA in solution before grafting this complex on surfaces. XPS analysis pointed out a lower amount of nisin on the surface for both approaches compared to the immobilization of nisin on native HA. However, an antibacterial activity was maintained, probably due to a higher local density of the AMP when surfaces were modified with hydrolyzed hyaluronic acid, leading to a better combination of antiadhesive-biocidal properties. Microscopy fluorescent observations demonstrated that accumulation of dead cells was also avoided by some coatings architecture.

Inactivation of vaccinia virus by a diffusible component from hydrolyzed hyaluronic acid [PMID: 13076197 · 1953]
MCCREA JF, DURAN-REYNALS F · Science (1953)

よくある質問 (FAQ)

Q1. 加水分解ヒアルロン酸 (HYDROLYZED HYALURONIC ACID) の各国公式全成分表示名称（7トラック）はどのように異なりますか？
日本化粧品工業連合会(JCIA)表示名称は '加水分解ヒアルロン酸'、米国PCPC・欧州CosIng INCIは 'HYDROLYZED HYALURONIC ACID'、中国NMPA IECIC標準中国語名は '水解透明质酸' です。
Q2. 加水分解ヒアルロン酸 (HYDROLYZED HYALURONIC ACID) のグローバル6大法域における法定配合基準 (Layer 1) は？
6大法域規制ステータス — 日本(JP): none、韓国(KR): none、欧州(EU): none、米国(US): none、中国(CN): allowed、ASEAN: none。
Q3. 処方設計における 加水分解ヒアルロン酸 (HYDROLYZED HYALURONIC ACID) の通常配合濃度 (Layer 3) と適正 pH は？
主要剤形 (aqueous_serum) において通常 0.05〜0.1%（中央値 0.1%）で配合され、適正pH範囲は 4〜8 です。
Q4. 加水分解ヒアルロン酸 (HYDROLYZED HYALURONIC ACID) の配合禁忌 (Incompatibilities) と推奨シナジー成分は？
推奨シナジーペアは GLYCERIN, CAPRYLIC/CAPRIC TRIGLYCERIDE, TOCOPHEROL、配合上の注意点は Verify phase compatibility under extreme pH or high electrolyte loads です。